Opioid dosing among patients with 3 or more years of continuous prescription opioid use before and after the CDC opioid prescribing guideline.

The International Journal on Drug Policy
Joanne SalasJeffrey F Scherrer

Abstract

Opioid doses declined after the Centers for Disease Control (CDC) opioid prescribing guideline was published. However, it is unknown if dose declines occurred in patients with ≥ 3 years of continuous opioid use. Optum® de-identified integrated Electronic Health Record and claims data were used to create an adult sample (n = 400) with continuous opioid use for 18 months before and after the guideline publication. Based on the morphine milligram equivalent (MME) distribution at Month 1, patients were categorized into 1-50, 51-100, 101-200, and >200 mg baseline MME. Interrupted time series analysis using segmented mixed linear regression models stratified on baseline MME estimated average monthly changes in MME in the 18-months pre- and post-guideline, before and after adjusting for time-varying pain conditions, psychiatric disorders and benzodiazepine prescription. Patients were 59.6 (SD±11.8) years of age, 55.8% female and 84.0% white race. For 1-50 MME, monthly dose slope was significantly (p<0.0001) flatter post-guideline (pre b = 0.34 MME/month vs. post b = 0.12 MME/month). For 51-100 MME, the pre- and post-guideline dose slopes did not significantly differ (pre b = 0.60 MME/month vs. post b = 0.27 MME/month). For 101-200 MME...Continue Reading

References

Aug 14, 2002·Journal of Clinical Pharmacy and Therapeutics·A K WagnerD Ross-Degnan
Oct 25, 2006·Archives of Internal Medicine·Mark D SullivanKenneth B Wells
Jan 20, 2010·Annals of Internal Medicine·Kate M DunnMichael Von Korff
Apr 7, 2011·JAMA : the Journal of the American Medical Association·Amy S B BohnertFrederic C Blow
Apr 13, 2011·Archives of Internal Medicine·Tara GomesDavid N Juurlink
Jan 20, 2015·Pain·Jeffrey F ScherrerUNKNOWN Residency Research Network of Texas (RRNeT) Investigators
May 27, 2015·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Gabrielle CampbellLouisa Degenhardt
Jan 13, 2016·Annals of Family Medicine·Jeffrey F ScherrerPatrick J Lustman
Feb 2, 2016·The Journal of Pain : Official Journal of the American Pain Society·Mark D SullivanGary M Franklin
Mar 16, 2016·JAMA : the Journal of the American Medical Association·Deborah DowellRoger Chou
Apr 16, 2016·American Journal of Preventive Medicine·Catherine S HwangJana K McAninch
Jul 20, 2017·Journal of the American Board of Family Medicine : JABFM·Matthew A DavisBrian D Sites
Sep 8, 2017·Pharmacoepidemiology and Drug Safety·Ramin Mojtabai
Jan 18, 2018·Preventive Medicine Reports·Matthew E HirschtrittMark Olfson
Mar 20, 2018·International Journal of Public Health·Sahar SaeedMarina B Klein
Nov 30, 2018·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Beth D DarnallTravis Lovejoy
Jan 29, 2019·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Kurt KroenkeMark Sullivan
Feb 12, 2019·JAMA Internal Medicine·Gery P GuyDeborah Dowell
Apr 25, 2019·Advances in Therapy·Joseph V PergolizziJo Ann LeQuang
Apr 25, 2019·The New England Journal of Medicine·Deborah DowellRoger Chou

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.